louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04790071: Dry Needling Treatment in Hemiplegic Shoulder Pain
Official title: Does Dry Needling Treatment Make an Extra Contribution to Conventional Treatment in Hemiplegic Shoulder Pain?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemiplegia
Shoulder Pain
Myofascial Pain
Keywords: Hemiplegic shoulder pain
Conventional treatment
Dry needling
Lead sponsor: Kars State Hospital
Sponsor class: OTHER
First posted: 2021-03-10
Enrollment: 46
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective randomised controlled
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy of dry needling therapy on shoulder pain and upper extremity functions in hemiplegic patients.

Detailed description: The myofascial trigger point is an overlooked issue in hemiplegic shoulder pain. Our aim in this study is to evaluate whether dry needling treatment contributes to the conventional treatment approach.

Eligibility criteria: Inclusion Criteria:

* The patients included in the study were aged between 30-60 years, with at least a 3-month history of hemorrhagic or ischemic stroke.

Exclusion Criteria:

* if they had severe difficulty in communication
* had received a corticosteroid injection within 3 months prior to enrollment
* had bleeding diathesis, a history of shoulder surgery
* a preexisting painful shoulder disorder, or had a cardiac pacemaker.

Primary outcomes:
measure: Change in visual analog scale score
timeFrame: 3 months
measure: Change in range of motion
timeFrame: 3 months
measure: Change in Quick The Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire score
timeFrame: 3 months
measure: Change in Fugl-Meyer Assessment score
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kars
country: Turkey
facility: Kars State Hosital
city: Kars
country: Turkey
facility: Kars State Hospital
Study officials:
affiliation: Kars State Hospital
name: Fatih Bagcier
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00221871: Proper Dosage of Ketamine in Intravenous Regional Anesthesia
Official title: Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain.
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2005-09-22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.


Eligibility criteria: Inclusion Criteria:

1. Age: 18-70
2. Weight: 50-100 kg
3. ASA: I, II, III
4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

Exclusion Criteria:

1. Contraindication to IVRA such as sickle cell disease.
2. Any known hypersensitivity reaction to Ketamine.
3. History of chronic pain or regular medication with analgesics.
4. History of opioid dependence.
5. Drug of alcohol abuse.
6. Psychiatric disorder.
7. Allergy to acetaminophen or codeine

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network
state: Ontario
Study officials:
affiliation: University Health Network, Toronto
name: Colin McCartney, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01917071: The Effect of Directional Specific Thoracic Spine Mobilization on Cervical Spine Pain
Official title: The Effect of Directional Specific Thoracic Spine Mobilization on Cervial Spine Pain.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Lead sponsor: Chatham University
Sponsor class: OTHER
First posted: 2013-08-06
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Hypothesis: There is no difference in directional specific manipulation of the thoracic spine for patients with neck pain.

Patients seeking physical therapy for neck pain routinely have their thoracic spine manipulated. This study seeks to determine if directional limitations in the spine can be specifically determined and treated to decrease neck pain.

Detailed description: Manipulation of the thoracic spine is the most commonly used manual therapy intervention by manual therapists. It is not known whether we can accurately assess and treat directional limitations in the thoracic spine to improve neck pain.

One way is to assess where the limitation is and treat it. Another method is to distract the joint. We want to know if matching the limitation to the manipulation method will give patients with neck pain better results.

The patient lays on their back. The therapist places a hand on the inferior vertebrae of the motion segment. The patient relaxes and the therapist pushes in an anterior to posterior direction either moving the vertebrae into flexion or entension.

Eligibility criteria: Inclusion Criteria:

* Patients with Neck Pain; ages 18 - 60

Exclusion Criteria:

* red flags: leg weakness, night pain, history of cancer, upper motor neuron signs, infection, tumors, osteoporosis, fracture (Boissonnault, 2011) (Cleland, 2004) history of whiplash within 6 weeks, cervical stenosis, CNS involvement, signs consistent with nerve root compression, previous surgery, pending legal action

Primary outcomes:
measure: Neck Disability Index
timeFrame: 2 weeks
Secondary outcomes:
measure: Neck Pain
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Chatham University
state: Pennsylvania
Study officials:
affiliation: Chatham University
name: Steve A Karas, DSc, PT
role: STUDY_DIRECTOR
References:
Clinical trial NCT01454271: Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate
Official title: Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Hip Arthroplasty Replacement
Keywords: Total Hip arthroplasty
Hip Osteoarthritis
Infection after Total Hip Arthroplasty
Lead sponsor: Laboratoire Ceraver-Osteal
Sponsor class: INDUSTRY
First posted: 2011-10-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The risk of infection after primary Total Hip Arthroplasties (THA)is generally estimated to be less than 1% but remains a severe and costly complication, source of morbidity and even mortality. The "biofilm" forms very early after the bacterial contamination of the prosthesis and poses a number of clinical challenges due to his resistance to immune defence mechanisms and antibiotics. Preventive strategies are needed. The poly sodium styrene sulfonate (pNaSS) is a bioactive polymer. In vitro and in vivo studies showed that poly sodium styrene sulfonate grafted on titane surfaces reduce significantly the bacterial adhesion. They also proved his biocompatibility and osseous-integration.


Eligibility criteria: Inclusion Criteria:

* Age less than 75 years old
* Aetiologies for THA : primary osteoarthritis, inflammatory diseases,Osteonecrosis

Exclusion Criteria:

* Previous infectious hip arthritis
* Previous surgeries on the operated hip
* Revision of THA

Primary outcomes:
measure: Femoral component osseous-integration
timeFrame: 1 year after surgery
Secondary outcomes:
measure: Infection rate
timeFrame: 1 year after surgery
measure: Quality of Life
timeFrame: One, three, six and twelve months after surgery
Other outcomes:
Locations:
city: Boulogne-Billancourt
country: France
facility: Ambroise Paré Hospital. Orthopaedic surgery department
state: Ile De France
Study officials:
affiliation: Ambroise Paré Hospital
name: Philippe Hardy, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05545371: Prevention of Rabies With Four Doses of Rabies Vaccine
Official title: Randomized, Blind and Positive Control Design: a Phase III Clinical Trial to Evaluate the Consistency Between Batches of 5 Doses of Freeze-dried Rabies Vaccine (Vero Cell) and the Immunogenicity and Safety of 4 Doses of Vaccine (1-1-1-1)
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE3
Conditions: Rabies Human
Antibody
Lead sponsor: Changchun Zhuoyi Biological Co., Ltd
Sponsor class: OTHER
First posted: 2022-09-19
Enrollment: 2100
Sex: ALL
Minimum age (years): 10
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program over the five dose immunization program and the batches consistency of immunogenicity according to five dose immunization procedures.

Detailed description: * In the population aged 10-60 years, evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program (0, 3, 7, 14/28 days) over the five dose immunization program (0, 3, 7, 14, 28 days)；
* To evaluate the consistency of immunogenicity between batches of freeze-dried human rabies vaccine (Vero cell) inoculated according to five dose immunization procedures (0, 3, 7, 14, 28 days).

Eligibility criteria: Inclusion Criteria:

* People aged 10-60；
* Body temperature on the day of enrollment\<37.3℃ (axillary temperature)

Exclusion Criteria:

* Have a history of rabies vaccine immunization or use of rabies virus passive immunization agents；
* People with congenital or acquired immunodeficiency or other autoimmune diseases；
* Female urine pregnancy test is positive, or during pregnancy and lactation, or she has a birth plan during the study period;

Primary outcomes:
measure: Positive conversion rate of 14 days
timeFrame: 6 months
measure: Antibody Geometric Mean Titer (GMT) of 14 days
timeFrame: 6 months
measure: Positive conversion rate of 42 days
timeFrame: 6 months
measure: Advertise Events (AE) incidence within 1 month
timeFrame: 6 months
measure: Serious Adverse Events (SAE) incidence within 6 months
timeFrame: 12 months
Secondary outcomes:
measure: Antibody test of 28 days
timeFrame: 6 months
measure: Antibody GMT of 42 days
timeFrame: 6 months
measure: Antibody test within 12 months
timeFrame: 18months
Other outcomes:
Locations:
city: Changchun
country: China
facility: Changchun Zhuoyi Biological Co., Ltd
state: Jilin
Study officials:
affiliation: Changchun Zhuoyi Biological Co., Ltd
name: Li Miao
role: STUDY_DIRECTOR
References:
Clinical trial NCT01237171: A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
Official title: Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: NSCLC
Non Small Cell Lung Cancer
Keywords: Brachytherapy
Lung Brachytherapy
NSCLC
Sub-lobar resection
Lead sponsor: IsoRay Medical, Inc.
Sponsor class: INDUSTRY
First posted: 2010-11-09
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with clinical stage I non-small cell lung cancer who are not candidates for full lobectomy.

Brief summary: For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is usually removed at surgery to treat the cancer. For some patients, the removal of a lobe of lung may leave too little lung behind for easy breathing. For some of these patients, it may be possible to perform a smaller-scale surgery ("sub-lobar resection") and place a radioactive implant behind to prevent the cancer from growing back. This study will see how these patients do in terms of controlling their disease treated with a radioactive implant called Cesium-131.


Eligibility criteria: Inclusion Criteria:

1. Patients must have suspicious lung nodule for clinical stage I/recurrent non-small cell Lung Cancer
2. Mass Tumor size \< 7 cm
3. Patient must have a CT scan of the chest with upper abdomen within 90 days prior to date of pre-registration.
4. Patient must have ECOG/Zubrod performance status 0,1, or 2.

Exclusion Criteria:

1. Patient has already received high dose radiation to the area
2. Cancerous nodule is very close to the esophagus or spinal cord, thereby increasing the risk of radiation treatment
3. Pregnancy or unwillingness to practice a form of birth control (i.e. abstinence, oral contraceptives, etc.)

Primary outcomes:
measure: Local Recurrence
timeFrame: 3 Years
Secondary outcomes:
measure: Quality of Life
timeFrame: 2 years
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Bhupesh Parashar, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01634971: External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDIDPD)
Official title: Phase II Study of External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Postoperative Fistula
Complications of Surgical and Medical Care: General Terms
Keywords: Postoperative pancreatic fistula(POPF);
Postpancreatectomy hemorrhage(PPH);
Delayed gastric emptying (DGE);
Bile leakage after pancreatic surgery;
Anastomotic leakage
Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
Sponsor class: OTHER
First posted: 2012-07-06
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Postoperative pancreatic fistula (POPF) and other surgical complications are common after pancreatoduodenectomy (PD) and POPF is a major complication. The drainage of pancreatic duct is important and a stent is usually placed in the operation, but it is still controversial whether the stent drainage is internal or external.

Detailed description: The current study is to compare the rate of Postoperative pancreatic fistula(POPF) and other surgical complications after pancreatoduodenectomy (PD).

Eligibility criteria: Inclusion Criteria:

* Age more than 18 years.
* Received pancreatoduodenectomy.
* Informed consent has been signed.

Exclusion Criteria:

* Age less than 18 years
* Emergency surgery
* Past history of pancreatic surgery.

Primary outcomes:
measure: the rate of Postoperative pancreatic fistula within 2 weeks after operation
timeFrame: within 2 weeks after operation
Secondary outcomes:
measure: the rate of postoperative Surgical Complications
timeFrame: 2 weeks after operation
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute and Hospital
state: Tianjin
Study officials:
affiliation: Tianjin Medical University Cancer Institute and Hospital
name: Qiang WU, MD. Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT03488771: Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients
Official title: Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Kidney Transplant Infection
Kidney Transplant Rejection
Keywords: kidney transplantation
rejection
infection
immunosuppression
Lead sponsor: Clinical Hospital Merkur
Sponsor class: OTHER
Collaborators: name: Clinical Hospital Centre Zagreb
First posted: 2018-04-05
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Kidney transplant recipients

Brief summary: All kidney transplant recipients require immunosuppression, the net level of which is difficult to assess. Current practice in assessing immune reactivity is to monitor levels of some immunosuppressive drugs. QuantiFERON Monitor® (QFM) is an in vitro diagnostic test that detects interferon-γ (IFN-γ) release in peripheral blood. Its clinical utility in assessment of the net state of immunosuppression in kidney transplant recipients has not been well studied. The aim of our study is to evaluate the discriminating value of QFM testing results for infection and rejection in a single-centre cohort of kidney transplant recipients.


Eligibility criteria: Inclusion Criteria:

* Kidney/Liver kidney/Simultaneous pancreas and kidney transplantation

Exclusion Criteria:

* none

Primary outcomes:
measure: Infection
timeFrame: throughout the study period (Kidney transplant recipients from 1 day date of tx to 15 years after tx)
Secondary outcomes:
measure: Rejection
timeFrame: throughout the study period (Kidney transplant recipients from 1 day date of tx to 15 years after tx)
Other outcomes:
Locations:
city: Zagreb
country: Croatia
facility: Clinical Hospital Merkur
state: HR
Study officials:
References:
Clinical trial NCT03739671: Vitamin D Supplementation and Effects on Mood in Emergency Medicine Residents
Official title: Correlation of Vitamin D Supplementation in Emergency Medicine Residents and Seasonal Mood Symptoms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Seasonal Mood Disorder
Lead sponsor: Spectrum Health - Lakeland
Sponsor class: OTHER
First posted: 2018-11-14
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Seasonal mood changes, and even feelings of depression, appear to have an association with decreased amounts of vitamin D in people living in geographic areas where exposure to sunlight during the winter months is relatively low. In this study, PGY-2 and PGY-3 Emergency Medicine residents at Lakeland Health will fill out PHQ-9 surveys for a total of 6 months (October-March), filled out at the end of each month. This is the time of year in southwest Michigan where exposure to direct sunlight is the lowest. The results of the individual surveys will be trended for the entire six months to see if individuals responds more positively after Vitamin D supplementation is initiated between months 3 and 4. Vitamin D supplementation will be 5000 units daily for the months of January-March.


Eligibility criteria: Inclusion Criteria:

* PGY-2 and PGY-3 Emergency Medicine Residents at Lakeland Health

Exclusion Criteria:

* Nonresidents and PGY-1 and PGY-4 Emergency Medicine residents at Lakeland Health

Primary outcomes:
measure: Effect of vitamin D on resident mood
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Joseph
country: United States
facility: Lakeland Regional Healthcare
state: Michigan
Study officials:
References:
Clinical trial NCT05319171: Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a Native Valve. The PANTHEON International Project.
Official title: Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a Native Valve. The PANTHEON International Project.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Aortic Regurgitation
Lead sponsor: IRCCS Policlinico S. Donato
Sponsor class: OTHER
First posted: 2022-04-08
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: inoperable patients with severe aortic regurgitation

Brief summary: * To investigate the performance of currently available THVs in terms of safety and efficacy
* To evaluate potential predictors of THV embolization or migration (TVEM)
* To assess the impact of TVEM on prognosis


Eligibility criteria: Inclusion Criteria:

* severe aortic regurgitation
* prohibitive surgical risk

Exclusion Criteria:

* surgical candidates

Primary outcomes:
measure: Overall mortality
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: IRCCS Policlinico S. Donato, Milan, Italy
state: Milan
Study officials:
References:
Clinical trial NCT00015171: Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1
Official title: CS1008 A&B Eff/Safety Trial of BUP/NX for the Treatment of Opiate Dependence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Heroin Dependence
Substance-Related Disorders
Keywords: opioid dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: New York MDRU
First posted: 2001-04-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is the use of buprenorphine/naloxone in treatment of opioid dependence.

Detailed description: The objective of this study is to determine the safety and efficacy of a buprenorphine/naloxone combination tablet for opiate dependence treatment.

Eligibility criteria: Inclusion Criteria:

DSM-IV diagnosis of current opiate dependence males and non-pregnant, non-nursing female 18-59 yrs of age

Exclusion Criteria:

Any significant medical condition AST or ALT levels greater than 3x's the upper limit of normal level Current Axis I diagnosis other than opiate, caffeine or nicotine dependence

Primary outcomes:
measure: Craving
measure: Drug use
measure: Retention
measure: Opioid withdrawal
measure: Subjective rating
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York MDRU
state: New York
Study officials:
affiliation: New York MDRU
name: John Rotrosen, M.D.
role: PRINCIPAL_INVESTIGATOR
References: